RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles of the face, décolleté and hands
Phase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01) is scheduled to deliver data in late-2016
Today’s edition of the Financial Post (Oct 27, 2015) highlights three Canadian companies (RepliCel Life Sciences Inc., Hemostemix Inc. and Sernova Corp.) making a global impact on the regenerative medicine industry and the pivotal role the Centre for Commercialization of Regenerative Medicine (CCRM) is taking to leverage commercialization.
First Participants Enrolled in RepliCel’s Phase 1 Clinical Trial of its RCS-01 Dermatology Injectable
Testing the use of a cell-based injectable as a regenerative alternative for the global dermal filler market addressing aged and UV-damaged skin
RepliCel Life Sciences has received approval to conduct a phase 1 trial in healthy volunteers investigating the potential of its skin rejuvenation product, RCS-01, to treat intrinsic aging of the skin, skin wrinkling and solar degeneration of the skin. RepliCel’s non-bulbar dermal sheath-derived fibroblast therapy (RCS-01) provides a promising treatment for these conditions by providing UV-naïve collagen-producing cells directly to affected areas. RepliCel’s unique manufacturing technology allows for isolation of fibroblasts derived from anagen-hair follicle mesenchymal tissue, which elicit efficient replication potential in culture. Furthermore, the proprietary culture conditions in which RCS-01 is manufactured should enable these cells to maintain their inherent ability to adapt to their microenvironment and respond to the surrounding stimuli after injection, leading to robust, natural production of type 1 collagen, elastin and other extracellular proteins within the tissue. The goal is to develop a first-of-its-kind treatment for fine wrinkles on sun-damaged skin.
German-based trial to test RCS-01 cell therapy treatment for aged and sun-damaged skin
Chronic Achilles tendinosis affects both physically active and inactive individuals accounting for 30 to 50% of all sports injuries and 50% of occupation-related disorders in the United States. The study will include 28 participants with chronic Achilles tendinosis. Study participants will receive ultrasound-guided injections of either RCT-01 or placebo (on a 3:1 treatment-to-placebo ratio) directly into areas of injury within the Achilles tendon. Participants’ overall health and tendinosis will be monitored over a six month period while they undergo post-treatment physiotherapy to help facilitate recovery from their Achilles tendinosis.
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative than drugs, and hence more valuable. That's the way Alain Vertès of NxR Biotechnologies sees it. In this interview with The Life Sciences Report, Vertès talks about some of the stem cell names he knows well, and draws comparisons investors can bank on.
As population gets older, local biotech companies aim to satisfy demand for youth-bestowing products. "Cell therapy is like personalized medicine. You don't have to pump yourself full of synthetics anymore. This uses your own cells," comments Lee Buckler, VP Business & Corp. Development, RepliCel Life Sciences.
Seeking to cure the incurable - Canada and Japan setting the world pace for innovations in regenerative medicine
National Post article highlights the important role the Centre for Commercialization of Regenerative Medicine (CCRM) is taking to help Canadian cell therapy companies like RepliCel Life Sciences (TSX.V: RP) create pathways for commercialization in Canada and Japan.
RepliCel's autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged and UV-damaged skin.
The Alliance for Regenerative Medicine's YouTube channel is a wealth of video content. If you've haven't checked it out lately, you owe it to yourself to do so.
Newly Released Peer-Reviewed Publication Further Validates RepliCel’s Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.